CRSP vs. TECH, QGEN, PCVX, EXEL, RGEN, RVMD, HALO, KRYS, ADMA, and SRRK
Should you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Bio-Techne (TECH), Qiagen (QGEN), Vaxcyte (PCVX), Exelixis (EXEL), Repligen (RGEN), Revolution Medicines (RVMD), Halozyme Therapeutics (HALO), Krystal Biotech (KRYS), ADMA Biologics (ADMA), and Scholar Rock (SRRK). These companies are all part of the "biological products, except diagnostic" industry.
CRISPR Therapeutics vs.
CRISPR Therapeutics (NASDAQ:CRSP) and Bio-Techne (NASDAQ:TECH) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, community ranking, earnings, dividends, profitability, analyst recommendations, valuation and risk.
CRISPR Therapeutics received 78 more outperform votes than Bio-Techne when rated by MarketBeat users. Likewise, 64.84% of users gave CRISPR Therapeutics an outperform vote while only 62.64% of users gave Bio-Techne an outperform vote.
CRISPR Therapeutics presently has a consensus price target of $78.38, suggesting a potential upside of 93.38%. Bio-Techne has a consensus price target of $82.00, suggesting a potential upside of 8.14%. Given CRISPR Therapeutics' higher possible upside, equities research analysts plainly believe CRISPR Therapeutics is more favorable than Bio-Techne.
Bio-Techne has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.
In the previous week, CRISPR Therapeutics had 12 more articles in the media than Bio-Techne. MarketBeat recorded 17 mentions for CRISPR Therapeutics and 5 mentions for Bio-Techne. CRISPR Therapeutics' average media sentiment score of 0.51 beat Bio-Techne's score of 0.42 indicating that CRISPR Therapeutics is being referred to more favorably in the media.
CRISPR Therapeutics has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.
69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 98.9% of Bio-Techne shares are owned by institutional investors. 4.1% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 3.9% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Bio-Techne has a net margin of 12.86% compared to CRISPR Therapeutics' net margin of -118.13%. Bio-Techne's return on equity of 12.76% beat CRISPR Therapeutics' return on equity.
Summary
Bio-Techne beats CRISPR Therapeutics on 10 of the 18 factors compared between the two stocks.
Get CRISPR Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CRISPR Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CRSP) was last updated on 1/20/2025 by MarketBeat.com Staff
Free CRSP Stock Alerts